Post-earnings recap
Reported
Wed, Nov 8, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Regeneron Pharmaceuticals reported a strong EPS, exceeding expectations, which contributed to a 2.67% increase in stock price. The lack of revenue data means investors will need to focus on other performance indicators. Management's positive tone suggests they are optimistic about future growth, particularly in their pipeline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.99 | N/A | +0.93% |
| Revenue | N/A | N/A | N/A |
Management expressed confidence in the company's current performance and future prospects. They highlighted the strength of their pipeline and ongoing projects.
We are pleased with our performance this quarter.
Our pipeline continues to show promise.